EC extends approval for Janssen’s daratumumab to include multiple myeloma patients
European Pharmaceutical Review | May 03, 2017
The European Commission (EC) has granted approval to Janssen‘s Daralex (daratumumab) for use in combination with lenalidomide and dexamethasone, or bortezomib (Velcade) and dexamethasone.